Lenomorelin
DRACPC ID DRACPC0068
Active Ingredients Lenomorelin
Description A 28 amino acid peptide hormone that was originally isolated from the stomach as the endogenous ligand for the growth hormone secretagogue receptor (GHSR). Ghrelin and its receptor are expressed in a number of cancers and cancer cell lines and may play a role in processes associated with cancer progression, including cell proliferation, apoptosis, and cell invasion and migration.
Synonyms Ghrelin; Ghrelin human; Human acylated ghrelin; Ghrelin (human); Lenomorelin
Type Biotech
Disease Cancer
Classification
Peptide and derivative Hormone and analogue
Structure Information
Molecular Formula C149H249N47O42
Molecular Weight 3370.9
Active Sequence GXSFLSPEHQRVQQRKESKKPPAKLQPR
Sequence Length 28
Modification X=Ser(octanoyl)
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID 91668172
DrugBank Accession Number DB11895
NCI Thesaurus Code C170105
UNII UXG268Q86R GSRS
CAS 258279-04-8
Drug approval
Drug indication
Lenomorelin has been investigated for the treatment and basic science of Cancer, Alcoholism, Metabolism, Hypopituitarism, and Frailty Syndrome, among others.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00681486 | Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss | Cancer | Phase 3 | Treatment |
| NCT00933361 | Individual Dose-escalated Bi-daily sc Ghrelin in Cancer Cachexia: a Phase I/II Study | Advanced Cancer； Cachexia | Phase 1/2 | Treatment |
| NCT02913703 | Effect of Preprandial Ghrelin on Postprandial Glucose Tolerance | Type 2 Diabetes | Phase 1 | Basic Science |
More clinical information is obtained from ClinicalTrials.gov.
